International
With over 70 years in the pharma industry and 280 different pharmaceutical products, Rekah is working to increase its international presence by focusing on out-licensing, in-licensing, establishing new partnerships and executing mergers and acquisitions.
We are focusing on adjusting our corticosteroid product line and additional niche products to regulatory requirements abroad.
Rekah is working to increase its international presence, focusing on the EU and other eCTD-based countries such as the Canada, Australia and others.
Our two manufacturing sites meet the EU’s GMP under the Mutual Recognition Agreements (MRAs) treaty between the Israeli Ministry of Health and the European Commission.
We are investing in R&D, regulatory and manufacturing capabilities for producing new generic products, and development of unique niche products to meet market requirements overseas.
We look for strategic collaborations in markets where our core products have a strong competitive added value.
Rekah is engaged in all aspects of the pharmaceuticals’ value chain - from manufacturing, importing, and marketing to distributing to the customer's doorstep.
Rekah owns a variety of marketing authorizations in Israel for several prescription drugs which are manufactured abroad.
At Rekah, we are looking for opportunities to expand our portfolio with additional complementary products.
Rekah is working to expand its business operations and achieve an international footprint, focusing on Europe.
Rekah seeks strategic partnerships that will enable it to expand its product portfolio, shorten its time to market (TTM) and obtain regulatory license in its chosen markets.
With strong financial backing, we aim to extend our business activities and make an international footprint, focusing on Europe and European-oriented pharmaceutical businesses.
Rekah is working to increase its international presence, focusing on the EU and other eCTD-based countries such as the Canada, Australia and others.
Our two manufacturing sites meet the EU’s GMP under the Mutual Recognition Agreements (MRAs) treaty between the Israeli Ministry of Health and the European Commission.
We are investing in R&D, regulatory and manufacturing capabilities for producing new generic products, and development of unique niche products to meet market requirements overseas.
We look for strategic collaborations in markets where our core products have a strong competitive added value.
Rekah is engaged in all aspects of the pharmaceuticals’ value chain - from manufacturing, importing, and marketing to distributing to the customer's doorstep.
Rekah owns a variety of marketing authorizations in Israel for several prescription drugs which are manufactured abroad.
At Rekah, we are looking for opportunities to expand our portfolio with additional complementary products.
Rekah is working to expand its business operations and achieve an international footprint, focusing on Europe.
Rekah seeks strategic partnerships that will enable it to expand its product portfolio, shorten its time to market (TTM) and obtain regulatory license in its chosen markets.
With strong financial backing, we aim to extend our business activities and make an international footprint, focusing on Europe and European-oriented pharmaceutical businesses.
OUT-LICENSING
Rekah is working to increase its international presence, focusing on the EU and other eCTD-based countries such as the Canada, Australia and others.
Our two manufacturing sites meet the EU’s GMP under the Mutual Recognition Agreements (MRAs) treaty between the Israeli Ministry of Health and the European Commission.
We are investing in R&D, regulatory and manufacturing capabilities for producing new generic products, and development of unique niche products to meet market requirements overseas.
We look for strategic collaborations in markets where our core products have a strong competitive added value.
IN-LICENSING
Rekah is engaged in all aspects of the pharmaceuticals’ value chain - from manufacturing, importing, and marketing to distributing to the customer's doorstep.
Rekah owns a variety of marketing authorizations in Israel for several prescription drugs which are manufactured abroad.
At Rekah, we are looking for opportunities to expand our portfolio with additional complementary products.
PARTNERSHIPS AND M&A
Rekah is working to expand its business operations and achieve an international footprint, focusing on Europe.
Rekah seeks strategic partnerships that will enable it to expand its product portfolio, shorten its time to market (TTM) and obtain regulatory license in its chosen markets.
With strong financial backing, we aim to extend our business activities and make an international footprint, focusing on Europe and European-oriented pharmaceutical businesses.
![/images/svg/international-out.svg]()
OUT-LICENSING
Rekah is working to increase its international presence, focusing on the EU and other eCTD-based countries such as the Canada, Australia and others.
Our two manufacturing sites meet the EU’s GMP under the Mutual Recognition Agreements (MRAs) treaty between the Israeli Ministry of Health and the European Commission.
We are investing in R&D, regulatory and manufacturing capabilities for producing new generic products, and development of unique niche products to meet market requirements overseas.
We look for strategic collaborations in markets where our core products have a strong competitive added value.
![/images/svg/international-in.svg]()
IN-LICENSING
Rekah is engaged in all aspects of the pharmaceuticals’ value chain - from manufacturing, importing, and marketing to distributing to the customer's doorstep.
Rekah owns a variety of marketing authorizations in Israel for several prescription drugs which are manufactured abroad.
At Rekah, we are looking for opportunities to expand our portfolio with additional complementary products.
![/images/svg/international-partner.svg]()
PARTNERSHIPS AND M&A
Rekah is working to expand its business operations and achieve an international footprint, focusing on Europe.
Rekah seeks strategic partnerships that will enable it to expand its product portfolio, shorten its time to market (TTM) and obtain regulatory license in its chosen markets.
With strong financial backing, we aim to extend our business activities and make an international footprint, focusing on Europe and European-oriented pharmaceutical businesses.